and THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A, as Trustee Third Supplemental Indenture dated as of August 13, 2019 to Indenture dated as of September 9, 2014Assertio Therapeutics, Inc • November 7th, 2019 • Pharmaceutical preparations • New York
THIRD SUPPLEMENTAL INDENTURE, dated as of August 13, 2019 (this “Supplemental Indenture”), between ASSERTIO THERAPEUTICS, INC., a Delaware corporation (the “Company”, as more fully set forth in Section 2.01), and THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., a New York banking association, as trustee (the “Trustee,” as more fully set forth in Section 2.01), supplementing the Indenture relating to “Senior Debt Securities” dated as of September 9, 2014, between the Company and the Trustee (the “Base Indenture” and, as amended and supplemented by this Supplemental Indenture, and as it may be further amended or supplemented from time to time with respect to the Notes, the “Indenture”).
CERTAIN MATERIAL (INDICATED BY [***]) HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCOSED. FIRST AMENDMENT TO SUPPLY AGREEMENTSupply Agreement • November 7th, 2019 • Assertio Therapeutics, Inc • Pharmaceutical preparations
This First Amendment to Supply Agreement (the “First Amendment”), dated as of July 11, 2019 (“First Amendment Effective Date”), is entered into by and between Assertio Therapeutics, Inc. f/k/a, Depomed, Inc., a company duly authorized and existing under the laws of Delaware, having its registered office at 100 S. Saunders Rd., Suite 300, Lake Forest, IL 60045 (hereinafter referred to as “Purchaser”), and Noramco, Inc., a Georgia corporation, having a place of business at 500 Swedes Landing Road, Wilmington, Delaware 19801 (hereinafter referred to as “Noramco”), to amend that certain Supply Agreement entered into between Purchaser and Noramco effective as of April 2, 2015 (the “Agreement”).
ASSERTIO THERAPEUTICS, INC. AMENDMENT NO 1 TO AMENDED AND RESTATED MANAGEMENT CONTINUITY AGREEMENTManagement Continuity Agreement • November 7th, 2019 • Assertio Therapeutics, Inc • Pharmaceutical preparations • Delaware
This Amendment No. 1 (the “Amendment”) to Amended and Restated Management Continuity Agreement (the “Agreement”) dated August 15, 2018 is effective as of August 6, 2019 (the “Effective Date”) by and between ______________________ (“Employee”) and Assertio Therapeutics, Inc., a Delaware corporation (the “Company”). This Amendment amends the Agreement solely as specified herein. All capitalized terms not defined in this Amendment shall have the meaning ascribed to such terms in the Agreement.
